Syntara’s SNT-5505 Receives FDA Fast Track Designation for Myelofibrosis Treatment

The latest update is out from Pharmaxis Ltd ( (AU:SNT) ).

Syntara Limited announced that its lead candidate, SNT-5505, has received Fast Track designation from the US FDA for treating myelofibrosis in patients with inadequate response to JAK inhibitor therapy. This designation, which expedites the review and development process, reflects the significant unmet medical need for effective treatments for this serious blood cancer. SNT-5505 has shown promise in clinical studies, demonstrating improved patient quality of life and a strong safety profile, positioning it as a potential new standard of care.

The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.25 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.

More about Pharmaxis Ltd

Syntara Limited is a clinical-stage biotechnology company based in Sydney, Australia, focused on developing first-in-class treatments for blood cancers and other fibrotic diseases.

Average Trading Volume: 7,978,002

Technical Sentiment Signal: Buy

Current Market Cap: A$112.1M

See more insights into SNT stock on TipRanks’ Stock Analysis page.